TBC 3711

Drug Profile

TBC 3711

Alternative Names: TBC3711

Latest Information Update: 14 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Encysive Pharmaceuticals
  • Class Anti-ischaemics; Heart failure therapies; Isoxazoles; Small molecules; Thiophenes
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cardiovascular disorders; Resistant hypertension

Most Recent Events

  • 11 Jun 2008 Encysive Pharmaceuticals has been acquired by Pfizer
  • 21 Mar 2007 Phase-II clinical trials in Resistant hypertension in USA (PO)
  • 12 Dec 2006 Phase-I clinical trials in Cardiovascular disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top